Evidence map›Paper›PMID 31163012›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.

Daniel J Ma, Katharine A Price, Eric J Moore, Samir H Patel, Michael L Hinni, Joaquin J Garcia, Darlene E Graner, Nathan R Foster, Brenda Ginos, Michelle Neben-Wittich and 11 more

Erratum issuedOpen access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 103 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 4 pooled it
21.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 4 syntheses or guidelines pooled it, 220 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Upfront Neck Dissection for Treatment Selection and Improvement in Quality of Life as a Novel Treatment Paradigm for Deintensification in HPV+ OPSCC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  7. Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial ofInternational journal of radiation oncology, biology, physics · 2023
    Trial
  8. Trial
  9. Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2023
    Trial
  10. Trial
  11. Trial
  12. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  13. Trial
  14. Review
  15. Article
  16. Article
  17. Does Smoking Influence Outcomes in Human Papillomavirus-Associated Oropharyngeal Cancer Treated with Transoral Robotic Surgery?Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
    Article
  18. Article
  19. Review
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Daniel J Ma1Mayo Clinic, Rochester, MN.
Katharine A Price1Mayo Clinic, Rochester, MN.
Eric J Moore1Mayo Clinic, Rochester, MN.
Samir H Patel2Mayo Clinic, Phoenix, AZ.
Michael L Hinni2Mayo Clinic, Phoenix, AZ.
Joaquin J Garcia1Mayo Clinic, Rochester, MN.
Darlene E Graner1Mayo Clinic, Rochester, MN.
Nathan R Foster1Mayo Clinic, Rochester, MN.
Brenda Ginos1Mayo Clinic, Rochester, MN.
Michelle Neben-Wittich1Mayo Clinic, Rochester, MN.
Yolanda I Garces1Mayo Clinic, Rochester, MN.
Ashish V Chintakuntlawar1Mayo Clinic, Rochester, MN.
Daniel L Price1Mayo Clinic, Rochester, MN.
Kerry D Olsen1Mayo Clinic, Rochester, MN.
Kathryn M Van Abel1Mayo Clinic, Rochester, MN.
Jan L Kasperbauer1Mayo Clinic, Rochester, MN.
Jeffrey R Janus1Mayo Clinic, Rochester, MN.
Mark Waddle3Mayo Clinic, Jacksonville, FL.
Robert Miller3Mayo Clinic, Jacksonville, FL.
Satomi Shiraishi1Mayo Clinic, Rochester, MN.
Robert L Foote1Mayo Clinic, Rochester, MN.
Mayo Clinic in Arizona · USMayo Clinic Hospital · USMayo Clinic in Florida · US

Funding

Paul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7M
NCI NIH HHS K12 CA090628
6 · The paper itself

Abstract

purposeThe purpose of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma could maintain historical rates for disease control while reducing toxicity and preserving swallow function and quality of life (QOL). PATIENTS AND

methodsMC1273 was a single-arm phase II trial testing an aggressive course of RT de-escalation after surgery. Eligibility criteria included patients with p16-positive oropharyngeal squamous cell carcinoma, smoking history of 10 pack-years or less, and negative margins. Cohort A (intermediate risk) received 30 Gy delivered in 1.5-Gy fractions twice per day over 2 weeks along with 15 mg/m

resultsAccrual was from September 2013 to June 2016 (N = 80; cohort A, n = 37; cohort B, n = 43). Median follow-up was 36 months, with a minimum follow-up of 25 months. The 2-year locoregional tumor control rate was 96.2%, with progression-free survival of 91.1% and overall survival of 98.7%. Rates of grade 3 or worse toxicity at pre-RT and 1 and 2 years post-RT were 2.5%, 0%, and 0%. Swallowing function improved slightly between pre-RT and 12 months post-RT, with one patient requiring temporary feeding tube placement.

conclusionAggressive RT de-escalation resulted in locoregional tumor control rates comparable to historical controls, low toxicity, and little decrement in swallowing function or QOL.

Indexed as

AgedAntineoplastic AgentsCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyCyclin-Dependent Kinase Inhibitor p16DeglutitionDisease-Free SurvivalDocetaxelDose-Response Relationship, RadiationFemaleFollow-Up StudiesHumansMaleMiddle AgedOropharyngeal NeoplasmsAntineoplastic AgentsCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Docetaxel

Identifiers

PMID31163012
PMCPMC7098832
OpenAlexW2948644893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.